DM
Deerfield Management Portfolio holdings
AUM
$5.51B
This Quarter Return
+18.6%
1 Year Return
+12.76%
3 Year Return
+152.98%
5 Year Return
+204.91%
10 Year Return
+993.1%
AUM
$6.69B
AUM Growth
+$6.69B
(+11%)
Cap. Flow
-$45.5M
Cap. Flow
% of AUM
-0.68%
Top 10 Holdings %
Top 10 Hldgs %
54.02%
Holding
681
New
246
Increased
84
Reduced
73
Closed
235
Top Buys
| 1 |
Neurocrine Biosciences
NBIX
|
$72.1M |
| 2 |
Indivior
INDV
|
$49.7M |
| 3 |
BCAX
Bicara Therapeutics Inc. Common Stock
BCAX
|
$45.7M |
| 4 |
Merus
MRUS
|
$32.9M |
| 5 |
Viatris
VTRS
|
$30.2M |
Top Sells
| 1 |
Gilead Sciences
GILD
|
$102M |
| 2 |
Surgery Partners
SGRY
|
$94.4M |
| 3 |
Catalyst Pharmaceutical
CPRX
|
$57.6M |
| 4 |
BioNTech
BNTX
|
$49.8M |
| 5 |
Integra LifeSciences
IART
|
$42.8M |
Sector Composition
| 1 | Healthcare | 87.45% |
| 2 | Industrials | 0.72% |
| 3 | Technology | 0.55% |
| 4 | Financials | 0.42% |
| 5 | Consumer Discretionary | 0.34% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Nuvalent
NUVL
$5.52B
| $2.05B | 30.56% | 19,991,024 | – | – |
|
|
2
Viatris
VTRS
$12.3B
| $279M | 4.16% | 23,993,023 +2,597,527 | +12% | +$30.2M |
|
3
Centene
CNC
$14.3B
| $200M | 2.98% | 2,652,189 +2,067 | +0.1% | +$156K |
|
|
4
Merus
MRUS
$4.98B
| $170M | 2.54% | 3,408,539 +659,138 | +24% | +$32.9M |
|
5
Oscar Health
OSCR
$4.31B
| $167M | 2.49% | 7,851,675 +891,888 | +13% | +$18.9M |
|
6
ARS Pharmaceuticals
SPRY
$1.15B
| $161M | 2.4% | 11,077,927 | – | – |
|
|
7
Neurocrine Biosciences
NBIX
$13.8B
| $152M | 2.27% | 1,316,590 +625,586 | +91% | +$72.1M |
|
8
Larimar Therapeutics
LRMR
$310M
| $139M | 2.08% | 21,231,974 | – | – |
|
|
WAY
9
Waystar Holding Corp
WAY
$6.6B
| $138M | 2.06% | 4,952,004 | – | – |
|
10
Revolution Medicines
RVMD
$7.1B
| $132M | 1.97% | 2,912,692 -177,381 | -6% | -$8.04M |
|
11
Alignment Healthcare
ALHC
$3.24B
| $128M | 1.92% | 10,854,985 -46,500 | -0.4% | -$550K |
|
|
12
Catalyst Pharmaceutical
CPRX
$2.52B
| $124M | 1.85% | 6,229,634 -2,897,671 | -32% | -$57.6M |
|
13
AdaptHealth
AHCO
$1.28B
| $109M | 1.63% | 9,711,410 -3,546,530 | -27% | -$39.8M |
|
14
Brookdale Senior Living
BKD
$1.83B
| $106M | 1.58% | 15,612,264 | – | – |
|
15
Kura Oncology
KURA
$686M
| $106M | 1.58% | 5,411,571 | – | – |
|
16
IDEAYA Biosciences
IDYA
$2.15B
| $82.2M | 1.23% | 2,594,000 +496,887 | +24% | +$15.7M |
|
17
Owens & Minor
OMI
$378M
| $77.1M | 1.15% | 4,911,979 -1,459,461 | -23% | -$22.9M |
|
18
Baxter International
BAX
$12.7B
| $73M | 1.09% | 1,923,100 +345,453 | +22% | +$13.1M |
|
19
BioCryst Pharmaceuticals
BCRX
$1.74B
| $61.8M | 0.92% | 8,135,804 | – | – |
|
|
20
Surgery Partners
SGRY
$2.91B
| $57.4M | 0.86% | 1,780,287 -2,927,000 | -62% | -$94.4M |
|
21
CVS Health
CVS
$92.8B
| $55M | 0.82% | 874,800 -100,200 | -10% | -$6.3M |
|
22
Cullinan Oncology
CGEM
$445M
| $54.9M | 0.82% | 3,280,000 -237 | -0% | -$3.97K |
|
23
Bio-Rad Laboratories Class A
BIO
$8.06B
| $50.7M | 0.76% | 151,575 -139 | -0.1% | -$46.5K |
|
24
Disc Medicine
IRON
$2.07B
| $50.3M | 0.75% | 1,023,265 | – | – |
|
|
25
Indivior
INDV
$3.03B
| $49.7M | 0.74% | +5,092,642 | New | +$49.7M |
|